Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Holding CPRX?
Track your performance easily
Catalyst Pharma (CPRX) Ownership Overview
6.28% Insiders
17.16% Mutual Funds
18.93% Other Institutional Investors
27.14% ETFs
30.49% Public Companies and Individual Investors
The ownership structure of Catalyst Pharma (CPRX) stock is a mix of institutional, retail, and individual investors. Approximately 63.23% of the company’s stock is owned by Institutional Investors, 6.28% is owned by Insiders, and 30.49% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Dec 11, 2024 | Steve Miller Chief Op. & Scientific Officer | xxxxxxxxxxxxx | $1096000 |
| Nov 29, 2024 | Molly Harper Director | xxxxxxxxxxxxx | $385000 |
| Nov 29, 2024 | Brian Elsbernd Chief Compliance/legal Officer | xxxxxxxxxxxxx | $85331 |
| Nov 29, 2024 | Gary Ingenito Chief Med. & Reg. Officer | xxxxxxxxxxxxx | $272644 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $412748 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $679796 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $718483 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $1725524 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,459,346 | Institution | 11.28% | 286,280,289 | |
| 6,826,313 | Institution | 5.72% | 145,195,678 | |
| 6,229,634 | Institution | 5.22% | 132,504,315 | |
| 5,225,389 | Institution | 4.38% | 111,144,024 | |
| 4,481,702 | Insider | 3.76% | 95,325,802 | |
| 3,184,389 | Institution | 2.67% | 67,731,954 | |
| 2,711,591 | Institution | 2.27% | 57,675,541 | |
| 2,242,940 | Institution | 1.88% | 47,707,334 | |
| 2,021,105 | Institution | 1.69% | 42,988,903 | |
| 1,730,869 | Institution | 1.45% | 36,815,584 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,225,389 | Institution | 4.38% | 111,144,024 | |
| 1,730,869 | Institution | 1.45% | 36,815,584 | |
| 1,300,847 | Institution | 1.09% | 27,669,016 | |
| 1,205,271 | Institution | 1.01% | 25,636,114 | |
| 1,184,753 | Institution | 0.99% | 25,199,696 | |
| 963,196 | Institution | 0.81% | 20,487,179 | |
| 899,586 | Institution | 0.75% | 19,134,194 | |
| 792,290 | Institution | 0.66% | 16,852,008 | |
| 742,200 | Institution | 0.62% | 15,786,594 | |
| 590,778 | Institution | 0.50% | 12,565,848 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,230,646 | Institution | 6.06% | 153,795,840 | |
| 3,532,746 | Institution | 2.96% | 77,013,863 | |
| 3,184,883 | Institution | 2.67% | 67,742,461 | |
| 2,728,801 | Institution | 2.29% | 58,560,069 | |
| 1,894,549 | Institution | 1.59% | 40,297,057 | |
| 1,663,762 | Institution | 1.39% | 36,270,012 | |
| 1,248,906 | Institution | 1.05% | 26,801,523 | |
| 1,113,595 | Institution | 0.93% | 23,686,166 | |
| 1,028,775 | Institution | 0.86% | 22,077,512 | |
| 1,017,994 | Institution | 0.85% | 21,652,732 |
FAQ
Who Owns Catalyst Pharma (CPRX)?
According to the latest TipRanks data, approximately 18.93% of the company's stock is held by institutional investors, 6.28% is held by insiders, and 30.49% is held by retail investors.
What percentage of Catalyst Pharma (CPRX) stock is held by institutional investors?
According to the latest TipRanks data, approximately 18.93% of Catalyst Pharma (CPRX) stock is held by institutional investors.
What percentage of Catalyst Pharma (CPRX) stock is held by retail investors?
According to the latest TipRanks data, approximately 30.49% of Catalyst Pharma (CPRX) stock is held by retail investors.
Who owns the most shares of Catalyst Pharma (CPRX)?
iShares owns the most shares of Catalyst Pharma (CPRX).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.